Printer Friendly

NantKwest and NantCell Receive FDA Authorization for the NANT Cancer Vaccine Clinical Trials.

M2 PHARMA-May 9, 2017-NantKwest and NantCell Receive FDA Authorization for the NANT Cancer Vaccine Clinical Trials

(C)2017 M2 COMMUNICATIONS

- The US Food and Drug Administration has authorised an Investigational New Drug Application for the NANT Cancer Vaccine for clinical trial enrollment for pancreatic cancer patients, US-based immunotherapy companies NantCell and NantKwest Inc. (NASDAQ: NK) said.

According to the company, the NANT Cancer Vaccine is the first combination immunotherapy protocol to orchestrate the delivery of metronomic low-dose radiation and chemotherapy with molecularly-informed, tumor-associated antigen vaccines and natural killer cells, to activate the innate and adaptive immune system and to induce immunogenic cell death.

By inducing immunogenic cell death and protecting as well as enhancing the innate and adaptive immune system, the NANT Cancer Vaccine seeks to attain long-term sustainable remission of multiple tumor types with lower toxicity and higher efficacy than current standards of care.

The NANT Cancer Vaccine is the first combination immunotherapy protocol to orchestrate the delivery of metronomic low dose radiation and chemotherapy with molecularly informed tumor associated antigen vaccines and natural killer cells, to activate the innate and adaptive immune system and to induce immunogenic cell death.

By inducing immunogenic cell death and protecting as well as enhancing the innate and adaptive immune system, the NANT Cancer Vaccine seeks to attain long-term sustainable remission of multiple tumor types with lower toxicity and higher efficacy than current standards of care.

NantKwest (NASDAQ: NK) is a developing next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer cells to treat cancer, infectious diseases and inflammatory diseases.

NK cells are the body's first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest's unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action.

These include direct killing using activated NK cells that release toxic granules directly into the cell through cell to cell contact, antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and Chimeric Antigen Receptor activated killing using taNKs, which are NK cells engineered to incorporate CARs to target tumor-specific antigens found on the surface of cancer cells.

The company's aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious "cytokine storms" reported after T cell therapy.

As an "off-the-shelf" therapy, NantKwest's NK cells do not rely on a patient's own often compromised immune system.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 9, 2017
Words:468
Previous Article:PureTech Health Starts Phase 2b mTORC1 Inhibitors Study.
Next Article:Nightingale Health and Oxford University's Nuffield Department of Population Health to work on metabolic biomarker profiling.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters